New Horizons in the Treatment and Management of Moderate to Severe Psoriasis: Tailoring Treatments to Achieve Improved Patient Outcomes and Quality of Life


New Horizons in the Treatment and Management of Moderate to Severe Psoriasis: Tailoring Treatments to Achieve Improved Patient Outcomes and Quality of Life is a 3-part webcast series that will provide attendees with the latest information in Psoriasis management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between January 12, 2018 to January 26, 2018.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the posttest to receive continuing education credits. If you do not pass the posttest after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your posttest, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.


This series is supported by an educational grant from Novartis Pharmaceuticals



During this three-part live webinar activity and subsequent enduring webcast and monograph, attendees will receive education that can not only assist them in developing the best strategy to improve outcomes for their psoriasis member population, but that education can also be passed along to their providers and patients (members) in an effort to better manage and support psoriasis patients, while improving outcomes, and quality of life. The webinars will explore critical aspects of the pathogenesis of psoriasis, updated safety and efficacy data on new biologic therapies that inhibit the IL-17 and IL-23 pathways, issues related to caring for patients not responding to traditional systemic treatments, strategies to manage treatment related adverse events, and strategic approaches to diagnosing and treating psoriasis. Attendees will leave with the ability to understand the disease prevalence and burden, management strategies for current and emerging therapies, combination therapy and managing side effects and co-morbidities, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.


This multi-part program on new horizons in the treatment and management of psoriasis will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.


A Deeper Look into IL-17 and IL-23 Inhibitors in the Management of Moderate to Severe Psoriasis: Exploring New Pathways to Clearer Skin

1.     Design individualized treatment plans for patients with moderate to severe psoriasis using clinical safety and efficacy data that take into account quality of life and the patient’s perspectives on disease severity and measures of treatment success

2.     Explore current clinical data on IL-17 and IL-23 pathway inhibitors and their respective mechanisms of action in the management of moderate to severe psoriasis

3.     Explain newer pathways for the development of plaque psoriasis and their implications for determining treatment, based on current evidence

4.     Analyze the most up-to-date diagnostic criteria and standard treatment options for moderate to severe psoriasis patients

5.     Provide a strategy to identify the appropriate patient populations who will benefit from IL-17 and IL-23 pathway inhibitors in moderate to severe psoriasis

Physician, Nursing and CMCN credits valid to February 28, 2019


Comparative Effectiveness and Coordinated Care in Moderate to Severe Psoriasis: What Does Managed Care Need to Know about Novel Biologic Therapies?

1.     Apply methods to enable optimal cost management of IL-17 and IL-23 inhibitors to be realized by multiple psoriasis stakeholders including managed care organizations

2.     Integrate interventions to coordinate health plan and affiliated provider's efforts that will lead to better outcomes for patients with psoriasis

3.     Analyze strategies used by managed care organizations to facilitate high quality care for members with moderate to severe psoriasis, and how newer therapies affect those strategies

4.     Assess comparative effectiveness information among newer biologic therapies, including IL-17 and IL-23 pathway inhibitors

Physician, Nursing and CMCN credits valid to February 28, 2019


Improving Patient Adherence and Quality of Life in Psoriasis: Strategies for Managing Treatment Related Adverse Events Associated with New Biologics

1.     Discuss challenges and barriers that healthcare professionals face when managing moderate to severe psoriasis

2.     Identify adverse events commonly associated with current and emerging IL-17 and IL-23 inhibitors used in the treatment of moderate to severe psoriasis

3.     Address challenges to patient adherence and quality of life and formulate strategies to manage treatment related adverse events associated with newer biologics

4.     Assess practical treatment considerations for patients with psoriasis who have challenging comorbidities

5.     Discuss the informational needs of patients and families/caregivers regarding their treatment plan and identify methods to counsel them

Physician, Nursing and CMCN credits valid to February 28, 2019